Press/Media
- 1 - 25 out of 33 results
Search results
-
Findings from Brigham and Women's Hospital Update Knowledge of Carcinomas (Cabozantinib Plus Nivolumab and Ipilimumab In Renal-cell Carcinoma)
22/08/23
1 item of Media coverage
Press/Media
-
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
3/03/23
2 items of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Demonstrates Positive Results for Renal Cell Carcinoma
27/02/23
1 item of Media coverage
Press/Media
-
Nivolumab-plus cabozantinib improves outcomes in advanced renal cell carcinoma
23/02/23
2 items of Media coverage
Press/Media
-
Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma
21/02/23
1 item of Media coverage
Press/Media
-
Nivolumab/cabozantinib shows improvements in long-term survival for RCC
19/02/23
2 items of Media coverage
Press/Media
-
Positive results for Ipsen 's Cabometyx in combination with nivolumab
17/02/23
1 item of Media coverage
Press/Media
-
Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation and its Symptoms
16/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
16/02/23
1 item of Media coverage
Press/Media
-
Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2
16/02/23
1 item of Media coverage
Press/Media
-
Opdivo-Cabometyx shows long-term effects in primary care of kidney cancer
15/02/23
2 items of Media coverage
Press/Media
-
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
15/02/23
1 item of Media coverage
Press/Media
-
Cabometyx and Opdivo show durable survival benefits in first-line advanced renal cell carcinoma
14/02/23
1 item of Media coverage
Press/Media
-
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
13/02/23 → 14/02/23
17 items of Media coverage
Press/Media
-
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
14/02/23
2 items of Media coverage
Press/Media
-
Cabometyx® in Combination with Nivolumab Shows Durable Survival Benefits At Over Three-years’ Follow-up in First-line Advanced Renal Cell Carcinoma
14/02/23
2 items of Media coverage
Press/Media
-
-
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
14/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma
13/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
13/02/23
1 item of Media coverage
Press/Media
-
Ipsen: Cabometyx in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
13/02/23
1 item of Media coverage
Press/Media
-
Cabometyx® In Combination With Nivolumab Shows Durable Survival Benefits At Over Three-Years' Follow-Up In First-Line Advanced Renal Cell Carcinoma
13/02/23
1 item of Media coverage
Press/Media